Grant: Discovery Grants Program - Individual
McGill University
$44,000.00
Mechanisms of Skin Barrier Integrity
FY 2024-25
Summary
Mammalian skin is a highly dynamic tissue in which its outermost layer composed of keratinocytes undergoes constant turnover and secretes an arsenal of soluble mediators that actively prevents microbial invasion. Keratinocyte-derived factors simultaneously condition underlying immune cells to ensure a rapid response if a breach in barrier integrity should occur. Within this context, leukocytes poised to produce the cytokine interleukin (IL)-17 dominate the skin immune cell repertoire because of their potent anti-microbial and wound-healing activity. However, environmental and/or genetic mechanisms that persistently amplifies keratinocyte activity can lead to uncontrolled IL-17 production that, in turn, destroy the skin barrier. Thus, our long-term goal is to define the molecular mechanisms underlying keratinocyte-mediated control of skin immune homeostasis.
With prior NSERC financial support, we recently reported that CD109, a GPI-anchored protein highly expressed in rodent and human skin, is an important determinant of cutaneous immune homeostasis (Zhang et al. Cell Reports 2019). Specifically, we demonstrated that mice genetically deficient in CD109 exhibit a defect in skin barrier integrity resulting in enhanced IL-17 secretion by innate-like ?d T cells (?d17 T cells) and spontaneous inflammation. Importantly, we demonstrated that CD109 was exclusively expressed by keratinocytes in vivo and selective elimination of CD109 in these structural cells was sufficient to disrupt skin homeostasis. However, the mechanism by which CD109 controls keratinocyte function remains unknown. Importantly, CD109 has been previously shown to regulate epidermal growth factor (EGF) receptor signaling, a robust regulator of keratinocyte differentiation. To investigate the cell-intrinsic mechanisms by which CD109 regulates keratinocyte function, we developed an in vitro primary keratinocyte culture system. Our unpublished data indicate that CD109 limits production of interleukin (IL)-1a, an `alarmin' released by stressed or dying cells to activate cutaneous inflammation. Consistent with these results, aberrant IL-1a secretion by keratinocytes was required for ?d17 T cell activation. Building on our published work and new preliminary data, our short-term goal is to identify how CD109 regulates the IL-17-EGFR-IL-1a axis in keratinocytes. We hypothesize that CD109 limits EGF receptor-mediated IL-1a secretion from keratinocytes to prevent aberrant ?d17 T cell activation. To test this hypothesis, we will complete three aims:
1.Determine whether CD109 regulates EGF receptor signaling in primary keratinocytes.
2.Dissect how CD109 regulates keratinocyte-derived IL-1a production.
3.Determine whether IL-17 amplifies an EGF receptor-IL-1a axis.
This research program will support the training of Canadian highly-qualified personnel to discover fundamental principles of cutaneous immune homeostasis and inform next generation tissue engineering strategies.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2023-03623
Name nom
King, Irah
Department département
Microbiology and Immunology
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
44000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5107
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell secretion
Research subject fr
Sécrétions cellulaires
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Mechanisms of Skin Barrier Integrity
Keywords
skin; keratinocytes; cytokines; cd109; epidermal growth factor; cell death
Application summary
Mammalian skin is a highly dynamic tissue in which its outermost layer composed of keratinocytes undergoes constant turnover and secretes an arsenal of soluble mediators that actively prevents microbial invasion. Keratinocyte-derived factors simultaneously condition underlying immune cells to ensure a rapid response if a breach in barrier integrity should occur. Within this context, leukocytes poised to produce the cytokine interleukin (IL)-17 dominate the skin immune cell repertoire because of their potent anti-microbial and wound-healing activity. However, environmental and/or genetic mechanisms that persistently amplifies keratinocyte activity can lead to uncontrolled IL-17 production that, in turn, destroy the skin barrier. Thus, our long-term goal is to define the molecular mechanisms underlying keratinocyte-mediated control of skin immune homeostasis.
With prior NSERC financial support, we recently reported that CD109, a GPI-anchored protein highly expressed in rodent and human skin, is an important determinant of cutaneous immune homeostasis (Zhang et al. Cell Reports 2019). Specifically, we demonstrated that mice genetically deficient in CD109 exhibit a defect in skin barrier integrity resulting in enhanced IL-17 secretion by innate-like ?d T cells (?d17 T cells) and spontaneous inflammation. Importantly, we demonstrated that CD109 was exclusively expressed by keratinocytes in vivo and selective elimination of CD109 in these structural cells was sufficient to disrupt skin homeostasis. However, the mechanism by which CD109 controls keratinocyte function remains unknown. Importantly, CD109 has been previously shown to regulate epidermal growth factor (EGF) receptor signaling, a robust regulator of keratinocyte differentiation. To investigate the cell-intrinsic mechanisms by which CD109 regulates keratinocyte function, we developed an in vitro primary keratinocyte culture system. Our unpublished data indicate that CD109 limits production of interleukin (IL)-1a, an `alarmin' released by stressed or dying cells to activate cutaneous inflammation. Consistent with these results, aberrant IL-1a secretion by keratinocytes was required for ?d17 T cell activation. Building on our published work and new preliminary data, our short-term goal is to identify how CD109 regulates the IL-17-EGFR-IL-1a axis in keratinocytes. We hypothesize that CD109 limits EGF receptor-mediated IL-1a secretion from keratinocytes to prevent aberrant ?d17 T cell activation. To test this hypothesis, we will complete three aims:
1.Determine whether CD109 regulates EGF receptor signaling in primary keratinocytes.
2.Dissect how CD109 regulates keratinocyte-derived IL-1a production.
3.Determine whether IL-17 amplifies an EGF receptor-IL-1a axis.
This research program will support the training of Canadian highly-qualified personnel to discover fundamental principles of cutaneous immune homeostasis and inform next generation tissue engineering strategies.